106 related articles for article (PubMed ID: 24157052)
1. A case of everolimus-associated chylothorax in a cardiac transplant recipient.
Fukushima N; Saito S; Sakata Y; Sawa Y
Transplant Proc; 2013 Oct; 45(8):3144-6. PubMed ID: 24157052
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
[TBL] [Abstract][Full Text] [Related]
3. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
4. Terminal Ileac Ulcers Mimicked Post-transplantation Lymphoproliferative Disorder in a Heart Recipient Treated With Everolimus: A Case Report.
Iwasaki K; Seguchi O; Mochizuki H; Kimura Y; Toda K; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Yanase M; Matsumoto Y; Fukushima S; Fujita T; Kobayashi J; Fukushima N
Transplant Proc; 2018 Dec; 50(10):4053-4056. PubMed ID: 30577313
[TBL] [Abstract][Full Text] [Related]
5. Fatal acute pulmonary injury associated with everolimus.
Depuydt P; Nollet J; Benoit D; Praet M; Caes F
Ann Pharmacother; 2012 Mar; 46(3):e7. PubMed ID: 22333263
[TBL] [Abstract][Full Text] [Related]
6. Rapidly progressive cardiac allograft vasculopathy in early onset regressed with everolimus treatment in an adult cardiac recipient.
Ishida J; Kinugawa K; Shiga T; Imamura T; Hatano M; Maki H; Inaba T; Yao A; Hirata Y; Nishimura T; Kyo S; Ono M; Nagai R
Int Heart J; 2012; 53(6):388-90. PubMed ID: 23258141
[TBL] [Abstract][Full Text] [Related]
7. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
Sparacino V; Calabrese S
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii34-7. PubMed ID: 16815856
[TBL] [Abstract][Full Text] [Related]
8. Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation.
Carreño CA; Gadea M
Transplant Proc; 2007 Apr; 39(3):594-5. PubMed ID: 17445552
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
[TBL] [Abstract][Full Text] [Related]
10. Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation.
Tsagalou EP; Anastasiou-Nana MI; Margari ZJ; Vassilopoulos D
J Heart Lung Transplant; 2007 Jun; 26(6):661-4. PubMed ID: 17543796
[TBL] [Abstract][Full Text] [Related]
11. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens.
Bortman GV; Ceruti B; Ahualli L; Colque R; Amuchástegui M; Sgrosso JL; Muñoz J; Vulcano N; Burgos C; Diez F; Rodriguez MC; Perrone SV
Transplant Proc; 2010; 42(1):324-7. PubMed ID: 20172342
[TBL] [Abstract][Full Text] [Related]
12. Reversible sirolimus-associated pneumonitis after heart transplantation.
Hamour IM; Mittal TK; Bell AD; Banner NR
J Heart Lung Transplant; 2006 Feb; 25(2):241-4. PubMed ID: 16446228
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
14. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study.
Fuchs U; Zittermann A; Hakim-Meibodi K; Börgermann J; Schulz U; Gummert JF
Transplant Proc; 2011 Jun; 43(5):1839-46. PubMed ID: 21693287
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in cardiac-transplant recipients.
Banas B; Böger C; Krämer B
N Engl J Med; 2003 Dec; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441
[No Abstract] [Full Text] [Related]
16. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
Kobashigawa J; Ross H; Bara C; Delgado JF; Dengler T; Lehmkuhl HB; Wang SS; Dong G; Witte S; Junge G; Potena L
Transpl Infect Dis; 2013 Apr; 15(2):150-62. PubMed ID: 23013440
[TBL] [Abstract][Full Text] [Related]
17. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
[TBL] [Abstract][Full Text] [Related]
18. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.
Masetti M; Rompianesi G; Montalti R; Romano A; Spaggiari M; Ballarin R; Guerrini GP; Gerunda GE
Transplant Proc; 2008; 40(6):1947-9. PubMed ID: 18675097
[TBL] [Abstract][Full Text] [Related]
19. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
Valantine H; Zuckermann A
J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
Celik S; Doesch A; Erbel C; Blessing E; Ammon K; Koch A; Katus HA; Dengler TJ
Transplantation; 2008 Jul; 86(2):245-50. PubMed ID: 18645486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
